Status:
COMPLETED
Resveratrol in Metabolic Syndrome: Effect on Platelet Hyper-reactivity and HDL Lipid Peroxidation
Lead Sponsor:
Vanderbilt University
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
30-75 years
Phase:
NA
Brief Summary
Metabolic syndrome is a group of risk factors that increase a patient's likelihood for heart attack, stroke and diabetes. Our research is aimed at understanding whether a drug, resveratrol, commonly f...
Detailed Description
Patients with metabolic syndrome are at increased risk of thrombotic complications, including myocardial infarction and cardiovascular death. A meta-analysis of the studies assessing cardiovascular ri...
Eligibility Criteria
Inclusion
- Metabolic Syndrome
Exclusion
- Evidence of coronary artery disease
- Indication for use of aspirin for secondary prevention of thrombotic events
- Use of non-steroidal anti-inflammatory drugs or anti-platelet agents
- Pregnancy
- Patients with history of bleeding or gastrointestinal ulcers
- Patients with major illnesses such as ongoing malignancies, infections, cirrhosis
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 7 2019
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT02219906
Start Date
May 1 2014
End Date
April 7 2019
Last Update
April 19 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University
Nashville, Tennessee, United States, 37232
2
Baylor University
Houston, Texas, United States, 77004